🔎 Trials Near Me

Hjem › Akut myeloid leukæmi › Iowa › Cedar Rapids

Akut myeloid leukæmi kliniske forsøg i Cedar Rapids, IA

16 studier for Akut myeloid leukæmi søger deltagere på steder i og omkring Cedar Rapids (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Mercy Hospital, Cedar Rapids
  • Oncology Associates at Mercy Medical Center, Cedar Rapids
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

RekruttererFase 1/2
  • University of Iowa Hospital, Iowa City · 25 mi væk
30 Days · Alle køn · Opdateret 16. sep. 2026 · NCT04065399

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

RekruttererObservationsstudie
  • University of Iowa Hospital and Clinics, Iowa City · 25 mi væk
Alder 0 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07154823

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

RekruttererFase 1
  • University of Iowa Health Care, Iowa City · 25 mi væk
Alder 18 til 75 · Alle køn · Opdateret 31. aug. 2026 · NCT07177079

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RekruttererFase 1/2
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi væk
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • University of Iowa Stead Family Children's Hospital, Iowa City · 25 mi væk
29 Days – 21 Years · Alle køn · Opdateret 24. aug. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • University of Iowa, Iowa City · 25 mi væk
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • University of Iowa Hospitals & Clinics, Iowa City · 25 mi væk
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

RekruttererFase 3
  • University of Iowa Hospitals and Clinics, Iowa City · 25 mi væk
Alder 18 til 75 · Alle køn · Opdateret 17. jul. 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservationsstudie
  • University of Iowa, Iowa City · 25 mi væk
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • University of Iowa Hospitals & Clinics, Iowa City · 25 mi væk
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184

Akut myeloid leukæmi forsøg i andre byer

Andre studier i Cedar Rapids

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.